Somatuline Depot

Base Information

• Chemical Name: Somatuline Depot
• CAS No.: 127984-74-1
• Molecular Formula: C₂H₄O₂*C₅₄H₆₉N₁₁O₁₀S₂
• Molecular Weight: 1156.39
• European Community (EC) Number: 694-399-4
• ChEMBL ID: CHEMBL1201184
• Mol file: 127984-74-1.mol

Synonyms:188Re-lanreotide;2-naphthylalanyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)-threoninamide;3-(2-naphthyl)-D-Ala-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;3-(2-naphthyl)alanyl-cystinyl-tyrosyl-tryptophyl-lysyl-valyl-cystinyl-threonine amide;angiopeptin;BIM 23014;BIM 23014 C;BIM 23014C;BIM-23014;BIM-23014 C;D-Nal-Cys-Tyr-Trp-Lys-Val-Cys-Thr-NH2;DC 13-116;DC-13-116;DC13-116;L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide;lanreotide;lanreotide acetate;lanreotide-SR;Nal-cyclo(Cys-Tyr-Trp-Lys-Val-Cys)-Thr-NH2;Nal-cyclo(Cys-Tyr-Trp-Lys-Val-Cys)Thr-NH2;naphthalenyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)threoninamide;naphthyl-cyclo(Cys-Tyr-Trp-Lys-Val-Cys)Thr-NH2;Somatulin;Somatulina;Somatuline

Chemical Property of Somatuline Depot

Chemical Property:

• Melting Point: >165°C (dec.)
• PSA: 997.86000
• LogP: 11.15110
• Storage Temp.: ?20°C
• Solubility.: DMSO (Slightly), Methanol (Slightly)
• Hydrogen Bond Donor Count: 14
• Hydrogen Bond Acceptor Count: 16
• Rotatable Bond Count: 17
• Exact Mass: 1155.48815915
• Heavy Atom Count: 81
• Complexity: 2030

Purity/Quality:

99%min, ^*data from raw suppliers

Lanreotide acetate ^*data from reagent suppliers

Safty Information:

• Hazard Codes: Xn
• Statements: 63
• Safety Statements: 36/37

MSDS Files:

Useful:

• Canonical SMILES: CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N.CC(=O)O
• Isomeric SMILES: C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O.CC(=O)O
• Recent ClinicalTrials: Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
• Recent EU Clinical Trials: A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial
• Description: Lanreotide acetate, an octapeptide somatostatin analog, reached its first worldwide market in France for acromegaly when surgery or radiotherapy have failed to restore normal growth hormone secretion. Lanreotide is a selective inhibitor of growth hormone and reduces the secretion of growth hormone, thyrotropin, motilin and pancreatic polypeptide in humans. Lanreotide has antiproliferative properties and is reportedly in clinical trials for the prevention of restenosis following coronary artery angioplasty, for diabetic retinopathy, and as a therapy for psoriasis. Its potential for neuroendocrine tumors and hormone-responsive prostate cancer has also been demonstrated.
• Uses: Lanreotide acetate has been used as an inhibitor to test the plasticity of hydrogen sulfide modulation by growth hormone/thyroid hormone signaling in wild-type mice. Lanreotide Acetate is a drug used in the control and prevention of glycemia and hypoglycemic brain damage without surgery in patients diagnosed with congenital hyperinsulinism. It improves outcomes in patients suffering from acromegalyresulting from invasive pituitary macroadenoma.

Technology Process of Somatuline Depot

There total 7 articles about Somatuline Depot which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

C102H115N11O14S2 + acetic acid (64-19-7,77671-22-8) → lanreotide acetate (2378114-72-6,127984-74-1)

Guidance literature:

C₁₀₂H₁₁₅N₁₁O₁₄S₂; With triethylsilane; methoxybenzene; trifluoroacetic acid; Cleland's reagent; In dichloromethane; at 25 - 30 ℃;

acetic acid; With iodine; In methanol; water; acetonitrile; at 15 - 30 ℃;

Reference yield:

H-D-β-Nal-Cys-(Acm)-Tyr-D-Trp-Lys-Val-Cys(Acm)-Thr-NH2 (1026080-86-3) + acetic acid (64-19-7,77671-22-8) → [cycloS-S]-3-(2-naphthyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide acetate (2378114-72-6,127984-74-1)

Guidance literature:

With iodine; In methanol; water; acetonitrile; at 15 - 30 ℃;

Reference yield:

C106H123N11O14S2 + acetic acid (64-19-7,77671-22-8) → [cycloS-S]-3-(2-naphthyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide acetate (2378114-72-6,127984-74-1)

Guidance literature:

C₁₀₆H₁₂₃N₁₁O₁₄S₂; With triethylsilane; 1,4-dithio-L-threitol; trifluoroacetic acid; In dichloromethane; at 2530 ℃;

acetic acid; In water; acetonitrile; at 15 - 30 ℃;

With iodine; In methanol; water; acetonitrile;

upstream raw materials:

acetic acid

lanreotide

H-D-β-Nal-Cys-(Acm)-Tyr-D-Trp-Lys-Val-Cys(Acm)-Thr-NH₂

ammonium acetate